Aerivio Spiromax (fluticasone propionate salmeterol xinafoate): Reviews and patient testimonials
Back to the list of medications
Medication indications
Aerivio Spiromax 50 microgram/500 microgram inhalation powder
Aerivio Spiromax is indicated for use in adults aged 18 years and older only.
Asthma
Aerivio Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:
- patients not adequately controlled on a lower strength corticosteroid combination product
or
- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.
Chronic Obstructive Pulmonary Disease (COPD)
Aerivio Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Route of administration: opinion.traitement.inhalation
Molecule: fluticasone propionate, salmeterol xinafoate
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.